SNCA and neoplasm: CPI-444 (an A2AR antagonist) moderately suppressed tumor growth, while combined with anti-PD-1 showed significant anti-tumor efficacy in vivo (causing tumor regression and improving survival), which might be related to the inhibition of PD-1 and LAG-3 expression by CPI-444 on CD8+ T cells and Tregs 170.